Menu Back toAntibody-Drug Conjugate Drug Development: From Novel Technology to New Patient Therapy

DIA 2021 Global Annual Meeting


Antibody-Drug Conjugate Drug Development: From Novel Technology to New Patient Therapy

Session Chair(s)

Angela  Qu, MD, PhD

Angela Qu, MD, PhD

  • Vice President, Translational Medicine
  • Parexel, United States
In this session, the expert speakers will describe and discuss the key learnings from this cutting-edge and arguably intriguing topic and promote open thoughts on how to innovate next-generation of ADC development and identify new opportunities to broaden ADC applications to deliver new therapies to help fulfill unmet medical needs.
Learning Objective : Illustrate up-to-date ADCs drug development landscape along with therapeutic applications and opportunities; Describe scientific rationales for Antibody-Drug Conjugate (ADC) drug design and novel technological platforms; Discuss case studies of novel ADCs development from bench to clinical and from clinical to successful launch; Discuss strategic and operational considerations unique to ADC including key challenges and translational needs for ADC drugs from preclinical into clinical.

Speaker(s)

Angela  Qu, MD, PhD

The Evolution of Antibody-Drug Conjugates in the Era of Precision Medicine Development

Angela Qu, MD, PhD

  • Vice President, Translational Medicine
  • Parexel, United States
Joern-Peter  Halle, PhD

Bispecific ADC Technology Platforms and M1231: A Bispecific ADC Targeting EGFR and MUC1

Joern-Peter Halle, PhD

  • Senior Vice President, Global Head of Research
  • Merck KGaA, Germany
Joanna B. Opalinska, MD

Before the DREAMM: Preclinical Findings Leading to Development of Belantamab Mafodotin

Joanna B. Opalinska, MD

  • Senior Director, Oncology Clinical Development
  • GlaxoSmithKline, United States